TrialNature communications2026

Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis.

Bo Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.